San Francisco, December 13th, 2019 – Recardio Inc., a clinical stage life science company developing regenerative therapies for cardiovascular diseases,announced the closing of its Series B financing round.
This closing includes existing shareholders as well as new undisclosed investors. The current proceeds will be used to complete the global Phase 2 study for Recardio’s lead therapeutic candidate, Dutogliptin, which is being developed for the treatment of acute myocardial infarction (AMI), commonly known as heart attack. The final closings will support the therapeutic and regional expansion of Recardio.
“The coming year will be both exciting and defining for Recardio as we will be completing our global Phase 2 trial with Dutogliptin for AMI, one of the most promising indications from our cardiovascular platform technology” said Dr. Roman Schenk, Recardio’s founder and Executive Chairman.
Recardio’s non-invasive regenerative approach can potentially play a significant role in improving the survival rate and quality of life for patients who experience a heart attack, as well as various other cardiovascular diseases.
Recardio Inc. is a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating SDF-1, a protein that is critical for cardiac regeneration. In addition to its current Phase 2 clinical program, Recardio will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival. For more information, visit: http://www.recardio.eu/